Last year, GSK plc generated 10.12B USD for its biggest-performing segment, HIV. The US made the largest contribution, accounting for 22.20B USD last year. For the latest quarter, GSK plc reported the revenue of 1.97B USD for the period ending 2022-12-31, which came from the top-performing segment, Respiratory. US contributed the highest revenue, at 5.78B USD.

By Business

Revenue

Proportion

Annual

Annual

Quarterly

HIV

Respiratory

Immuno-inflammation

Shingles

Established Vaccines

Other General Medicines

Oncology

Meningitis

RSV

Influenza

Pandemic Vaccines

Pandemic

Established Pharmaceuticals

Wellness

Oral Health

Nutrition

Skin Health

Unallocated

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

HIV

10.12B(23.53%)

9.06B(22.59%)

8.01B(21.25%)

7.09B(19.61%)

6.57B(19.34%)

6.25B(20.12%)

6.19B(14.38%)

Respiratory

9.31B(21.64%)

9.22B(22.99%)

8.48B(22.50%)

8.07B(22.33%)

8.32B(24.49%)

7.70B(24.79%)

3.93B(9.13%)

Immuno-inflammation

5.02B(11.66%)

4.21B(10.51%)

3.76B(9.97%)

3.22B(8.90%)

2.79B(8.21%)

2.21B(7.10%)

782.20M(1.82%)

Shingles

4.69B(10.89%)

4.30B(10.72%)

4.28B(11.36%)

3.65B(10.09%)

2.37B(6.97%)

2.55B(8.21%)

2.31B(5.36%)

Established Vaccines

4.11B(9.55%)

4.27B(10.64%)

4.06B(10.77%)

3.80B(10.52%)

4.08B(12.03%)

4.14B(13.33%)

4.83B(11.22%)

Other General Medicines

3.91B(9.09%)

4.11B(10.25%)

4.22B(11.19%)

4.40B(12.17%)

4.98B(14.65%)

5.48B(17.64%)

--(--)

Oncology

2.60B(6.05%)

1.80B(4.49%)

908.62M(2.41%)

742.02M(2.05%)

672.38M(1.98%)

477.00M(1.54%)

293.49M(0.68%)

Meningitis

2.08B(4.85%)

1.84B(4.58%)

1.57B(4.15%)

1.38B(3.81%)

1.32B(3.89%)

1.32B(4.25%)

1.30B(3.02%)

RSV

781.01M(1.82%)

753.77M(1.88%)

1.54B(4.08%)

--(--)

Influenza

399.07M(0.93%)

521.25M(1.30%)

626.46M(1.66%)

880.07M(2.43%)

933.63M(2.75%)

939.90M(3.02%)

690.33M(1.60%)

Pandemic Vaccines

--(--)

186.45M(0.49%)

78.89M(0.22%)

614.63M(1.81%)

--(--)

Pandemic

--(--)

15.33M(0.04%)

54.69M(0.15%)

2.85B(7.87%)

1.32B(3.88%)

--(--)

Established Pharmaceuticals

--(--)

11.20B(26.00%)

Wellness

--(--)

5.78B(13.41%)

Oral Health

--(--)

3.41B(7.92%)

Nutrition

--(--)

1.50B(3.48%)

Skin Health

--(--)

791.14M(1.84%)

Unallocated

--(--)

61.25M(0.14%)

By Region

Revenue

Proportion

Annual

Annual

Quarterly

Rest of world

Europe

Consumer Healthcare

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

22.20B(51.61%)

20.93B(52.22%)

19.66B(52.16%)

17.92B(49.59%)

20.75B(44.24%)

18.66B(42.69%)

17.72B(41.15%)

Rest of world

10.90B(25.33%)

18.25B(45.53%)

17.17B(45.55%)

17.36B(48.04%)

24.81B(52.90%)

23.80B(54.44%)

24.14B(56.06%)

Europe

9.92B(23.06%)

--(--)

904.53M(2.26%)

861.39M(2.29%)

856.65M(2.37%)

1.34B(2.86%)

1.26B(2.87%)

1.20B(2.79%)

Consumer Healthcare

--(--)

1.28M(--)

--(--)